Pharma Stocks with High DII Holding

The table below shows the pharma stocks with high DII holdings based on the highest market capitalization.

What Are The Pharma Stocks with High DII Holding?

Pharma stocks with high Domestic Institutional Investor (DII) holding refer to shares of pharmaceutical companies where a significant percentage of the stock is owned by domestic financial institutions. High DII holding often signifies robust domestic confidence in the company’s growth prospects, financial stability, and long-term potential in the pharmaceutical sector, potentially leading to increased stock value and market credibility.

Features Of Top Pharma Stocks with High DII Holding

The feature of top pharma stocks with high DII holding includes strong domestic confidence in their growth potential and stability, as evidenced by substantial investment from domestic institutions.

1. Solid Financial Performance: Companies consistently demonstrate robust revenue growth and profitability, attracting substantial domestic investment.
2. Innovative R&D: High DII holding firms invest heavily in research and development, leading to a strong pipeline of new drugs and therapies.
3. Regulatory Compliance: These companies maintain high standards of regulatory compliance, ensuring market trust and operational sustainability.
4. Market Leadership: Often, these firms hold leading positions in their market segments, showcasing strong competitive advantages and strategic positioning.
5. Strong Governance: High DII holding is associated with firms that exhibit excellent corporate governance practices, enhancing transparency and investor confidence.

Best Pharma Stocks with High DII Holding

The table below shows the best pharma stocks with high DII holding based on the highest day Volume.

Top Pharma Stocks with High DII Holding in India

The table below shows the top pharma stocks with high DII holding in India based on 1-Year Return. 

Factors To Consider When Investing In Pharma Stocks with High DII Holding

The factor to consider when investing in pharma stocks with high DII holdings is the stability these investments bring due to the involvement of institutional investors.

1. Growth Potential: Assess the company’s pipeline for new drugs and therapies, which can drive future revenue and profit growth.
2. Financial Health: Examine the company’s balance sheet, profitability, and cash flow to ensure financial stability.
3. Regulatory Environment: Understand the impact of regulatory approvals and compliance on the company’s operations and profitability.
4. Market Position: Evaluate the company’s market share, competitive edge, and brand reputation in the pharmaceutical industry.
5. Innovation and R&D: Look into the company’s investment in research and development, a key driver of long-term success in the pharma sector.

How To Invest In Pharma Stocks with High DII Holding?

To invest in pharma stocks with high DII holdings, open a trading account with a brokerage such as Alice Blue here. Research potential stocks, focusing on their financial health, growth potential, and market position. Stay informed about industry trends and regulatory changes. Diversify your investments to manage risks effectively, and consider consulting a financial advisor for personalized guidance.

Advantages Of Investing In Pharma Stocks with High DII Holding

The primary advantage of investing in pharma stocks with high DII holding is the potential for stable returns due to institutional investors’ extensive research and long-term perspectives.

1. Expert Analysis: Benefit from the thorough research and analysis performed by institutional investors.
2. Stability: Enjoy potential stability and reduced volatility due to significant institutional ownership.
3. Growth Potential: Gain from the growth prospects of companies heavily backed by knowledgeable investors.
4. Market Confidence: Higher DII holdings often reflect strong market confidence in the company’s future.
5. Long-term Focus: Institutional investors usually have a long-term investment horizon, aligning with sustainable growth.

Risks Of Investing In Pharma Stocks with High DII Holding

The main risk of investing in pharma stocks with high DII holding is the potential for sudden market reactions to regulatory changes or clinical trial outcomes, leading to significant stock price volatility.

1. Regulatory Risks: Changes in regulations can negatively impact stock performance.
2. Clinical Trials: Unsuccessful clinical trials can lead to substantial financial losses.
3. Market Sentiment: Stocks can be affected by overall market sentiment, causing volatility.
4. Dependency: High dependence on a few key products can be risky if those products face issues.
5. Exit Strategy: Large institutional investors may sell off shares, leading to sudden price drops.

Introduction to Pharma Stocks with High DII Holding 

Aurobindo Pharma Ltd

The Market Cap of Aurobindo Pharma Ltd is Rs. 77,976.71 crore. The stock’s monthly return is 8.03%. Its one-year return is 77.18%. The stock is 5.94% away from its 52-week high.

Aurobindo Pharma Limited is an Indian pharmaceutical company that specializes in manufacturing and marketing various pharmaceutical products and services. The company’s product range covers seven therapeutic areas including Central Nervous System, Antiretrovirals, Cardiovascular, and Oral Cephalosporins. 

Aurobindo Pharma is also developing oncology and hormonal products, as well as topical and transdermal products in dermatology. They are working on three depot injections using advanced technology platforms.  

Gland Pharma Ltd

The Market Cap of Gland Pharma Ltd is Rs. 32,795.48 crores. The stock’s monthly return is 7.76%. Its one-year return is 67.12%. The stock is 10.22% away from its 52-week high.

Gland Pharma Limited is a company based in India that specializes in generic injectables. They focus on producing complex injectables and operate within the sterile injectables, oncology, and ophthalmology sectors. 

The company offers services such as contract and in-house development, dossier preparation and filing, technology transfer, and manufacturing for different delivery systems. Their products are available in various forms including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops.  

Suven Pharmaceuticals Ltd

The Market Cap of Suven Pharmaceuticals Ltd is Rs. 20,889.60 crore. The stock’s monthly return is 15.84%. Its one-year return is 68.87%. The stock is 8.42% away from its 52-week high.

Suven Pharmaceuticals Limited, headquartered in India, specializes in the development and production of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals, and formulated drugs. 

The company offers contract research and manufacturing services to global pharmaceutical, biotechnology, and chemical firms. Operating in the Pharmaceuticals Manufacturing and Services sector, the company has a presence in various regions including India, the United States, Europe, and other countries. 

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is Rs. 19534.87 crore. The stock’s monthly return is -4.42%. Its one-year return is 49.58%. The stock is 12.71% away from its 52-week high.

Piramal Pharma Limited, an Indian pharmaceutical company, provides a range of unique pharmaceutical products through both domestic and international distribution channels. With around 17 facilities worldwide and a distribution network spanning over 100 countries, the company encompasses various subsidiaries. 

These include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing entity; Piramal Critical Care (PCC), a specialized hospital generics business; and the consumer healthcare division in India, which markets over-the-counter products.  

Granules India Ltd

The Market Cap of Granules India Ltd is Rs. 12,191.15 crore. The stock’s monthly return is 8.50%. Its one-year return is 60.47%. The stock is 5.50% away from its 52-week high.

Granules India Limited is an Indian pharmaceutical manufacturer operating within and outside India. The company is involved in the production of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs), and finished dosages (FDs). 

With over eight manufacturing facilities, most located in India and one in the United States, Granules India Limited sells its products globally in markets such as the USA, Canada, Latin America, Europe, Asia Pacific, and India.  

Wockhardt Ltd

The Market Cap of Wockhardt Ltd is Rs. 11,913.88 crore. The stock’s monthly return is 43.72%. Its one-year return is 245.44%. The stock is 28.11% away from its 52-week high.

Wockhardt Limited is a company operating in the pharmaceutical and biotechnology industry. Its activities involve the production and promotion of a wide range of pharmaceutical and bio-pharmaceutical products, active pharmaceutical ingredients (APIs), and vaccines. 

The company manufactures various types of dosage forms, such as sterile injectables and lyophilized products. Wockhardt offers a diverse portfolio of products in the areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy, and diabetology. 

Orchid Pharma Ltd

The Market Cap of Orchid Pharma Ltd is Rs. 6,583.59 crore. The stock’s monthly return is 8.66%. Its one-year return is 112.07%. The stock is 4.77% away from its 52-week high.

Orchid Pharma Limited, an Indian pharmaceutical company, specializes in the production of various active pharmaceutical ingredients (API). The company operates within the pharmaceutical sector and offers a range of products in multiple therapeutic areas such as anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular (CVS), nutraceuticals, and other oral and sterile products. 

The company’s product portfolio includes APIs and finished dosage forms encompassing Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products, and Non-Antibodies.  

Shilpa Medicare Ltd

The Market Cap of Shilpa Medicare Ltd is Rs. 6,161.81 crore. The stock’s monthly return is 20.10%. Its one-year return is 98.58%. The stock is 8.71% away from its 52-week high.

Shilpa Medicare Limited is an Indian pharmaceutical company that focuses on research and development, manufacturing, and sales of oncology drugs and formulations. The company’s product range includes oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, organic intermediates, pilot and production scales, and transdermal patches. 

Shilpa Medicare Limited supplies oncology APIs and intermediates worldwide. Its oncology and non-oncology APIs are supplied to various regulated markets such as the United States, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.  

Ami Organics Ltd

The Market Cap of Ami Organics Ltd is Rs. 5369.47 crore. The stock’s monthly return is -0.69%. Its one-year return is 12.52%. The stock is 11.91% away from its 52-week high.

Ami Organics Limited, an India-based company, specializes in manufacturing specialty chemicals with various applications. They primarily focus on developing and producing pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) as well as new chemical entities (NCEs). 

The company produces intermediates for several APIs such as dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban which are used in therapeutic areas like anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant drugs.  

Innova Captab Ltd

The Market Cap of Innova Captab Ltd is Rs. 3193.72 crore. The stock’s monthly return is 13.95%. Its one-year return is 3.08%. The stock is 5.36% away from its 52-week high.

Innova Captab Ltd, founded in 2005, is an integrated pharmaceutical company based in Panchkula, India. It engages in research and development, manufacturing, distribution, and marketing of generic pharmaceutical products both domestically and internationally.

Top Pharma Stocks with High DII Holding – FAQs

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.